AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02015780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antihyperglycemic therapy
Description: Including any of the following alone or in combination: insulin, sulfonylurea, thiazolidinediones, glucagon-like peptide-1 (GLP-1) receptor agonists, meglitinides, alpha-glucosidase inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors acceptable by local practice guidelines.
Study NCT01631409 — intervention group
Intervention type: DEVICE
Intervention: Cardiospec
Description: Cardiac shock wave therapy is implemented by device Cardiospec manufactured by Medispec Ltd.
Study NCT01631409 — intervention group
Intervention type: DRUG
Intervention: Aspirin, Isosorbide mononitrate, Atenolol, Enalapril
Description: In the course of maximal antianginal medical therapy a Cohort VI patient is provided with more than two groups of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
Study NCT04052269 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sildenafil 100mg
Description: study drug (Sildenafil or Tadalafil) administered orally in pill form with glass of water.
Study NCT04052269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 100mg
Description: study drug (Sildenafil or Tadalafil) administered orally in pill form with glass of water.
Study NCT02976623 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: metric-based feedback training
Description: Structured feedback; a trained investigator will give feedback according to a set of metrics and errors previously developed and validated. Trainees will undergo deliberate practice on the volunteer until they demonstrate adequate and objective performance as assessed by the set of metrics and errors provided.
Study NCT01195428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 40 mg daily
Study NCT01974258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Escalating dose
Study NCT01974258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Orally administered once daily for 21 consecutive days, followed by 7 days off.
Study NCT01195428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02576561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TVGV-1
Description: Antigen + Adjuvant
Study NCT01974258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Description: Administered by IV infusion every 2 weeks
Study NCT02576561 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GPI-0100
Description: Adjuvant Alone
Study NCT02576561 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04919278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic adjustments
Description: Chiropractic adjustment is a procedure in which trained specialists (chiropractors) use their hands or a small instrument to apply a controlled, sudden force to a spinal joint. The goal of this procedure, also known as spinal manipulation, is to improve spinal motion and improve your body's physical function.
Study NCT01870583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine povidone
Description: Iodine skin preparation solution prior to cesarean delivery
Study NCT01870583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Chlorhexidine skin preparation solution prior to cesarean delivery
Study NCT01870583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination iodine and chlorhexidine
Description: Combination iodine povidone and chlorhexidine skin preparation solution prior to cesarean delivery
Study NCT02456142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caudal bupivacaine
Study NCT02456142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous morphine
Study NCT03287440 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COPD Wellness
Description: This is low-intensity pulmonary rehabilitation that incorporates exercise, nutrition, patient education, and a support group class.
Study NCT03287440 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Advocate
Description: The Zuckerberg San Francisco General (ZSFG) Hospital Health Advocates program links social needs screening with a tiered referral and linkage process to appropriate resources
Study NCT01684631 — intervention group
Intervention type: DEVICE
Intervention: Total Hip arthroplasty
Study NCT02615054 — intervention group
Intervention type: DEVICE
Intervention: 2D Echocardiogram
Description: All patients will undergo a two-dimensional echocardiogram with speckle tracking strain analysis within the MSK echocardiography laboratory.
Study NCT01974258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Orally administered twice daily
Study NCT02615054 — intervention group
Intervention type: DEVICE
Intervention: Cardiopulmonary exercise testing and post-CPET cardiac function
Description: To determine VO2peak, an electronic motorized treadmill test with 12-lead ECG monitoring (Mac ® 5000, GE Healthcare) will be performed by certified exercise physiologists.
Study NCT02492347 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocardiogram
Description: The ECG is a non-invasive screening tool. It will be performed when the neonate is settled and comfortable. The electrodes used are made with soft jelly adhesive which is stored at room temperature. The procedure will be conducted in a timely manner, taking no longer than 15 minutes. The electrodes are easily removed, and the neonate redressed.
Study NCT02492347 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electrocardiogram
Description: The ECG is a non-invasive screening tool. It will be performed when the neonate is settled and comfortable. The electrodes used are made with soft jelly adhesive which is stored at room temperature. The procedure will be conducted in a timely manner, taking no longer than 15 minutes. The electrodes are easily removed, and the neonate redressed.
Study NCT04187560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LB-102
Description: (N-Methyl amisulpride)
Study NCT01159236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 by vein over about 1-2 hours once every 7 days x 12 courses.
Study NCT02068261 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual can consist of medication, psychotherapy, counseling, and psychological assessment.
Study NCT02261311 — intervention group
Intervention type: OTHER
Intervention: Quality of Life
Description: All participants recruited will complete a questionnaire prior to their breast biopsy and then again approximately one week before their surgery. The questionnaire is focused on the level of anxiety patients experience during the wait time between diagnosis and surgery. Additional tissue will be collected at the time of the diagnostic biopsy.
Study NCT03201445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: 200 mg tablet administered orally once daily
Study NCT03201445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match filgotinib tablet administered orally once daily
Study NCT03201445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Locally approved treatment, accepted by medical experts as a proper treatment for IBD conditions, prescribed according to best clinical practice, with no known testicular toxicity.
Study NCT03201445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Locally approved treatment, accepted by medical experts as a proper treatment for IBD conditions, prescribed according to best clinical practice, with no known testicular toxicity.
Study NCT04005885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A
Description: Contact Lens
Study NCT01159236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 500 mg/m2 for 4 courses (once every 7 days)
Study NCT04005885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A
Description: daily disposable contact lens
Study NCT04005885 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenfilcon A
Description: daily disposable contact lens
Study NCT01881906 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Study NCT01881906 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Study NCT02678156 — intervention group
Intervention type: DEVICE
Intervention: Lyoplant Onlay
Study NCT00827112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc
Description: maraviroc (Selzentry, Celsentri) 150mg QD + atazanavir (Reyataz) /ritonavir (Norvir) (300/100mg) QD OR maraviroc (Selzentry, Celsentri) 150mg QD+ darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR maraviroc (Selzentry, Celsentri) 150mg QD+ lopinavir/ritonavir (Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
Study NCT03955003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Drumming
Description: Cancer patients will be led by a Board Certified Music Therapist to participate in group drumming for one hour per week, for six weeks.
Study NCT03955003 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Attention Control
Description: This is intended to control for time, place, and group affect.
Study NCT03507959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OLP scientifically-objective
Description: Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a scientifically-objective manner.
Study NCT00827112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc
Description: emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + lopinavir/ritonavir(Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
Study NCT01197976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEPSO cloth
Description: TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
Study NCT03507959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OLP personally-affective
Description: Participants are informed that they are about to take a placebo. The rationale for the effectivity of placebos is explained in a personally-affective manner.
Study NCT03507959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DP scientifically-objective
Description: Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a scientifically-objective manner.
Study NCT03507959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DP personally-affective
Description: Participants are informed that they are about to take an effective antidepressant. The rationale for the effectivity of the antidepressant is explained in a personally-affective manner.
Study NCT01399632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Fat and High Carbohydrate Diet
Description: Low Fat and High Carbohydrate Diet
Study NCT01399632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Fat and Low Carbohydrate Diet
Description: High Fat and Low Carbohydrate Diet
Study NCT01197976 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard cloth
Description: Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
Study NCT02120703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregablin 75 mg per oral two times a day
Study NCT02120703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 200 mg twice daily per oral
Study NCT03821272 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PepCan
Description: 50 μg peptide + 0.3mL Candin® per dose administered intradermally in the extremities
Study NCT03347279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Tezepelumab
Description: Tezepelumab subcutaneous injection
Study NCT03347279 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study NCT05542472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Support Program Based on a Nurse-Led Case Management Model
Description: A Family Support Program Based on the Nurse-Led Case Management Model create for the care givers in the intervention group. Case management is the process of planning an individual's care, coordinating it, managing it, implementing it and reviewing it. The aim in case management is to improve a person's quality of life by coordinating health care services and providing these services at a reasonable cost and in a productive way. The use of case management requires the cooperation of professionals from many different disciplines. Therefore, in areas where case management is applied, the case manager coordinates an individual's or patient's care by enabling this cooperation. In this way, in areas where health services are provided, the case manager may be a doctor, a nurse, a physiotherapist, a social services expert, or a speech therapist.
Study NCT03264027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon dioxide
Description: Carbon dioxide will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
Study NCT03264027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambient air
Description: Ambient air will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
Study NCT03264027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Argon fulguration
Description: The dilatated anastomosis from the gastric bypass surgery will be reduced in diameter using fulguration with argon. Patient in both groups will be placed in the left lateral decubitus position, with anesthesia being performed exclusively using propofol; adequate cardiopulmonary monitoring will be carried out during the entire procedure. After sedation, endoscopy will be performed with an Olympus CV-180 endoscope (Olympus, Tokyo, Japan) and analysis and measurement of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). The images will be transferred to an Olympus EvisExera II processor connected to a computer with the ZScan 5 program (Goiânia, GO, Brazil).
Study NCT03264027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argon fulguration
Description: The dilatated anastomosis from the gastric bypass surgery will be reduced in diameter using fulguration with argon. Patient in both groups will be placed in the left lateral decubitus position, with anesthesia being performed exclusively using propofol; adequate cardiopulmonary monitoring will be carried out during the entire procedure. After sedation, endoscopy will be performed with an Olympus CV-180 endoscope (Olympus, Tokyo, Japan) and analysis and measurement of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). The images will be transferred to an Olympus EvisExera II processor connected to a computer with the ZScan 5 program (Goiânia, GO, Brazil).
Study NCT01741584 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stationary bike exercise
Study NCT01741584 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: aerobic
Study NCT02430675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
Study NCT02430675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study NCT00311623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin 3mg
Description: Rapamycin 3mg (Wyeth Pharmaceuticals, 1mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
Study NCT04343612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Subjects received a micro-current through their scalp to induce cortical and subcortical changes
Study NCT04343612 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Subjects received a micro-current through their scalp to induce cortical and subcortical changes
Study NCT02530281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycopyrronium Topical Wipes
Description: Topical wipes containing glycopyrronium
Study NCT02530281 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle (placebo) topical wipes
Study NCT03855358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450 Injection and Anlotinib Hydrochioride Capsules
Description: TQB2450 1200mg intravenously (IV) every-3-weeks (Q3W) and Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Study NCT04815915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graston technique
Description: Graston tool was used to treat patients 3 times in a week according protocol for 6 weeks' treatment plan with extensions bised exercises protocol following pattern of APTA.
Study NCT00963469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: montelukast 10 mg tablet orally once daily in the morning for 4 weeks
Study NCT00963469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: loratadine
Description: loratadine 10 mg tablet orally once daily in the morning for 4 weeks
Study NCT00963469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: placebo tablet orally once daily in the morning for 4 weeks
Study NCT01435564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone
Description: Participants in this group will receive both the pedometer and the mobile-phone based physical activity intervention fot three months.
Study NCT03821272 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Saline solution per dose administered intradermally in the extremities
Study NCT01292564 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia MLS
Description: The Erchonia MLS emits 635 nm low level laser light.
Study NCT01292564 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: The Placebo Laser looks identical to the Erchonia MLS Laser but emits no therapeutic light.
Study NCT06339138 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT01952990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Description: 1 spray device is 0.2mL (200 μL) in volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl. Subjects receiving the 100 μL dose will receive half of the contents of one device using a dose divider. Subjects receiving the 200 μL dose will first receive half of the contents of one device using a dose divider and then 4 minutes later will receive the 2nd half by removing the dose divider. Subjects receiving the 400 μL dose will first receive the entire contents of one device and then 4 minutes later will receive the contents of a 2nd device.
Study NCT00311623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin 6mg
Description: Rapamycin 6mg (Wyeth Pharmaceuticals, 2mg tablets) PO once daily on Days 1-14 with the last dose given on the morning before surgery (Day 15).
Study NCT00311623 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical prostatectomy
Description: Radical prostatectomy performed on Day 15
Study NCT01159236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments
Study NCT02624193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR Program
Description: Mindfulness-based stress reduction, as described previously.
Study NCT02624193 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: HT Program
Description: Health education curriculum, as described previously
Study NCT02248207 — intervention group
Intervention type: DRUG
Intervention: Pramipexole
Study NCT01159236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 100 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments, may be given instead of Doxorubicin in Group 1 and 2.